[An effect of 3-oxypyridine and succinic acid derivatives on the time of reduction of anxiety and depression symptoms in alcohol withdrawal treatment].

Abstract

To compare the effect of 3-oxypyridine and succinic acid derivatives (emoxypine, reamberin, mexidol) on the time of reduction of anxiety and depression symptoms in the standard treatment of alcohol withdrawal syndrome (AWS). A short-term prospective placebo-controlled double blind randomized study of the effect of emoxypine, reamberin, mexidol on the dynamics of reduction of anxiety and depression clinical symptoms in the course of a 14-day day hospital treatment of AWS was conducted. The severity of anxiety symptoms was assessed on a daily basis by using the Hamilton Anxiety Rating Scale (HARS). Symptoms of depression were assessed with the Montgomery-Asberg Depression Rating Scale (MADRS). Reduction of certain objective anxiety and depression symptoms was noticed at 0 point of the corresponding HARS and MADRS items. On the 1st and 14th day of treatment, the Zung Self-Rating Anxiety Scale (ZSRAS) and the Beck Depression Inventory (BDI) were additionally used. All the studied drugs reduced the duration of certain anxiety and depression symptoms during AWS treatment. The degree of this effect depended on the features of the chemical structure of a drug. Mexidol accelerated the reduction of «dread», «respiratory» and «cardiovascular» anxiety symptoms (HARS) by 25-50%. «Reduced appetite» and «concentration difficulty» (MADRS) improved by 28.5%. Reamberin reduced the duration of «gastrointestinal» and «respiratory» anxiety symptoms (HARS) by 17-50% and «inner tension» (MADRS) by 7%. Emoxypine accelerated the reduction of «insomnia» and «respiratory» symptoms (HARS) but did not affect the duration of objective depression symptoms (MADRS). Emoxypine and reamberin reduced the severity of affective and cognitive symptoms (BDI) by 32-37%. None of the drugs affected self-reported anxiety (ZSRAS). The most balanced treatment of depressive symptoms was provided by reamberin, which was the only of the studied drugs that simultaneously reduced both the duration of objective symptoms and the severity of subjective disorders of affective status in alcohol withdrawal.